Patents Examined by James O. Wilson
  • Patent number: 9567318
    Abstract: The present subject matter relates to a compound represented by the general formula (I) or (I?) or a pharmacologically acceptable salt thereof; pharmaceutical compositions containing at least one of these compounds; methods of making at least one of these compounds; methods of using at least one of these compounds for treating and/or preventing various cancers and/or proliferation disorders; methods of using at least one of these compounds for monitoring the effectiveness of an anticancer therapy against various cancers. In one embodiment, the subject matter relates to compounds that bind with a level of specificity to heat shock protein 70 (Hsp70). In another embodiment, the subject matter relates to compounds that bind with a level of specificity to inhibit both heat shock protein 70 (Hsp70) and heat shock cognate protein 70 (Hsc70).
    Type: Grant
    Filed: August 17, 2010
    Date of Patent: February 14, 2017
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Gabriela Chiosis, Tony Taldone, Anna Rodina, Pallav Patel, Yanlong Kang
  • Patent number: 9539261
    Abstract: The present invention provides methods and compositions comprising compounds useful for stimulating neurogenesis. The methods and compositions comprising compounds are also useful for inhibiting neuronal degeneration. Thus, the present invention can be used in the treatment of diseases and conditions characterized by neuronal loss and reduced neurogenesis including Alzheimer's disease, stroke, traumatic brain injury, and depression. This invention could also be used for research products including single agents or mixtures of agents to promote, proliferate, differentiate, or maintain neurons from stem or progenitor cells.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: January 10, 2017
    Assignee: Neuronascent, Inc.
    Inventor: Judith Kelleher-Andersson
  • Patent number: 9540326
    Abstract: Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1?), as well as hypoxia inducible factor-2 (HIF-2). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed compounds. Yet further disclosed are methods for stimulating the cellular immune response in a mammal such as increasing phagocytosis, for example, prolonging the life of phagocytes, inter alia, kerotyiocytes, neutrophils. As such the disclosed compounds provide methods for treating diseases that relate to the body's immune response.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: January 10, 2017
    Assignee: AERPIO THERAPEUTICS, INC.
    Inventors: Joseph H. Gardner, Robert Shalwitz
  • Patent number: 9539255
    Abstract: The present invention provides a solid form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: January 10, 2017
    Assignee: CELGENE AVILOMICS RESEARCH, INC.
    Inventor: Mei Lai
  • Patent number: 9533978
    Abstract: The invention concerns compounds of Formula (I): wherein L1, R1, R2, R3, R4 and X are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the treatment of disease, for example cancer.
    Type: Grant
    Filed: August 26, 2014
    Date of Patent: January 3, 2017
    Assignee: Sumitomo Dainippon Pharma Co., Ltd
    Inventors: Nicholas James Bennett, Stephen Thom, Thomas McInally
  • Patent number: 9513284
    Abstract: The invention provides a novel class of reactive fluorescent agents that are based on a pyrene sulfonic acid nucleus. The agents are readily incorporated into conjugates with other species by reacting the reactive group with a group of complementary reactivity on the other species of the conjugate. Also provided are methods of using the compounds of the invention to detect and/or quantify an analyte in a sample. In an exemplary embodiment, the invention provides multi-color assays incorporating the compounds of the invention.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: December 6, 2016
    Assignee: LIFE TECHNOLOGIES CORPORATION
    Inventors: Richard Haugland, Wai-Yee Leung, Jixiang Liu
  • Patent number: 9504682
    Abstract: The invention relates to compounds of Formula I, wherein R1, R2, and R3 are defined in the specification, useful for the synthesis of novel conjugates and immunogens derived from aripiprazole. The invention also relates to conjugates of an aripiprazole hapten and a protein.
    Type: Grant
    Filed: August 20, 2013
    Date of Patent: November 29, 2016
    Assignee: Janssen Pharmaceutica NV
    Inventors: Ronghui Lin, Rhys Salter, Thomas R. DeCory, Eric Hryhorenko, Bart Remmerie, Banumathi Sankaran
  • Patent number: 9505748
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNa, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: November 29, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, John S. Tokarski, Shuqun Lin, Steven H. Spergel, Yanlei Zhang
  • Patent number: 9486530
    Abstract: Gancyclovir formulations that are ready-to-use, substantially particulate free, and stable upon storage are disclosed. Methods of manufacture and administration of such compositions are also provided.
    Type: Grant
    Filed: September 2, 2014
    Date of Patent: November 8, 2016
    Assignee: Exela Pharma Sciences, LLC
    Inventors: Sreerama Murthy Mallipeddi, Jonathan E. Sterling, Phanesh B. Koneru
  • Patent number: 9487491
    Abstract: Provided is a compound useful as an inhibitor against the kinase activity of EML4-ALK fusion protein. As a result of intensive and extensive studies on compounds having inhibitory activity against the kinase activity of EML4-ALK fusion protein, the present inventors found that the diamino heterocyclic carboxamide compounds of the present invention had inhibitory activity against the kinase activity of EML4-ALK fusion protein. By this finding, the present invention was completed. The compounds of the present invention can be used as a pharmaceutical composition for preventing and/or treating cancer, such as lung cancer, non-small cell lung cancer, and small cell lung cancer.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: November 8, 2016
    Assignees: ASTELLAS PHARMA INC., KOTOBUKI PHARMACEUTICAL CO., LTD.
    Inventors: Itsuro Shimada, Kazuo Kurosawa, Takahiro Matsuya, Kazuhiko Iikubo, Yutaka Kondoh, Akio Kamikawa, Hiroshi Tomiyama, Yoshinori Iwai
  • Patent number: 9481648
    Abstract: There are provided compounds of formula I, wherein R1A to R1E, R2 to R5, L and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: November 1, 2016
    Assignees: Respivert Limited, Topivert Pharma Limited
    Inventors: Thomas Matthew Baker, Matthew Colin Thor Fyfe, Gareth William Harbottle, Vedran Hasimbegovic, Premji Meghani, Aaron Rigby, Colin Sambrook-Smith, Stephen Malcolm Thom
  • Patent number: 9458146
    Abstract: A crystalline sodium salt of a compound of formula I (INN: Raltegravir) or a hydrate/solvate thereof is disclosed as well as a process for obtaining the same.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: October 4, 2016
    Assignee: SANDOZ AG
    Inventors: Frtiz Blatter, Katharina Reichenbächer, Robert Ziegert, Josef Wieser, Johannes Ludescher
  • Patent number: 9452997
    Abstract: The present invention relates to piperidine and pyrazine derivatives according to formulae (Ia), (Ib) and (II) as autotaxin inhibitors and the use of such compounds for the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by increased lysophosphatic acid levels and/or the activation of autotaxin, in particular of different cancers.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: September 27, 2016
    Assignee: MERCK PATENT GMBH
    Inventors: Kai Schiemann, Melanie Schultz, Wolfgang Staehle
  • Patent number: 9447052
    Abstract: This invention relates to methods of making a compound of formula (I) and intermediates for same the compounds of formula (I) being useful for treating cardiovascular and inflammatory diseases such as atherosclerosis.
    Type: Grant
    Filed: May 17, 2011
    Date of Patent: September 20, 2016
    Assignee: Glaxo Group Limited
    Inventors: Kevin Stuart Cardwell, Claire Frances Crawford, Suzanne Helen Davies, Charles Edward Wade
  • Patent number: 9439903
    Abstract: The field of the invention relates to a process for the preparation of amorphous imatinib mesylate. In particular, the invention relates to a process for the preparation of stable amorphous imatinib mesylate. More particularly, the invention relates to pharmaceutical compositions that includes the stable amorphous imatinib messylate together along with its excipients.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: September 13, 2016
    Assignee: Cadila Healthcare Limited
    Inventors: Shriprakash Dhar Dwivedi, Kumar Kamlesh Singh, Ganpant Dan Shimbu Charan, Chetan Jayantibhai Vasava
  • Patent number: 9440949
    Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: September 13, 2016
    Assignee: Pfizer Inc.
    Inventors: Shawn Cabral, Kentaro Futatsugi, David Hepworth, Kim Huard, Daniel Wei-Shung Kung, Suvi Tuula Marjukka Orr, Kun Song
  • Patent number: 9434721
    Abstract: A compound of formula: wherein Ar1, A, R3, x, and m are as disclosed herein and Ar2 is a benzothiazolyl, benzooxazolyl, or benzoimidazolyl group or a pharmaceutically acceptable salt thereof (a “Benzoazolylpiperazine Compound”), compositions comprising a Benzoazolylpiperazine Compound, and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of a Benzoazolylpiperazine Compound are disclosed.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: September 6, 2016
    Assignee: Purdue Pharma L.P.
    Inventors: Qun Sun, Laykea Tafesse, Sam Victory
  • Patent number: 9428439
    Abstract: The invention provides an acid addition salt of a compound of the formula (1). Also provided by the invention are processes for preparing the compound of formula (1) and alkyl analogs thereof, novel intermediates for use in the process and methods for preparing the intermediates. The invention also provides new medical uses of compounds of the formula (1) and its ethyl analog.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: August 30, 2016
    Assignee: ASTEX THERAPEUTICS LTD.
    Inventors: Martyn Frederickson, John Francis Lyons, Neil Thomas Thompson, Mladen Vinkovic, Brian John Williams, Andrew James Woodhead, Alison Jo-Anne Woolford
  • Patent number: 9428533
    Abstract: The present invention provides compounds of the formula, wherein A, B, G, R2, R6, and X are defined herein, pharmaceutical compositions of the same, and methods for treating or inhibiting development of AGE- and/or ALE-associated complications in subjects in need thereof.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: August 30, 2016
    Assignee: Nephrogenex, Inc
    Inventors: Raja G. Khalifah, Roger E. Marti
  • Patent number: 9422247
    Abstract: The invention relates to iron(III) complex compounds and pharmaceutical compositions comprising them for the use as medicaments, in particular for the treatment and/or prophylaxis of iron deficiency symptoms and iron deficiency anemias.
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: August 23, 2016
    Assignee: Vifor (International) AG
    Inventors: Thomas Bark, Wilm Buhr, Susanna Burckhardt, Michael Burgert, Camillo Canclini, Franz Dürrenberger, Felix Funk, Peter Otto Geisser, Aris Kalogerakis, Simona Mayer, Erik Philipp, Stefan Reim, Diana Sieber, Jörg Schmitt, Katrin Schwarz